Grifols SA
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Grifols SA
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 79% of sales in 2017. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics grew to almost 20% of revenue in 2014 with the acquisition of Novartis' diagnostics unit.
/ 
Frequently asked questions
To buy Grifols SA stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Grifols SA by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Grifols SA is GRF:xmce. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Grifols SA has its primary listing on BME Spanish Exchanges. You can trade Grifols SA with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Grifols SA is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Grifols SA as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Grifols SA.